Shionogi

4507 · TSE · Japan

Public Market Listing

4507TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Shionogi are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
5Approved
2Phase 3 / Filed
0Phase 1–2 / Early
8Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Dolutegravir(Tivicay / Triumeq / Dovato / Juluca (component))
Approved
HIV integraseSmall molecule
HIV
Approved
Reactive oxygen species (ROS)Small molecule
Amyotrophic Lateral Sclerosis
Elvitegravir(Stribild)
Approved
HIV integraseSmall molecule
HIV
Approved
HMG-CoA reductaseSmall molecule
Atherosclerotic Cardiovascular DiseaseHomozygous Familial HypercholesterolemiaCardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Approved
Aryl hydrocarbon receptor · Aryl Hydrocarbon Receptor AgonistSmall molecule
Atopic DermatitisPsoriasis
Phase 3
CETPSmall molecule
Atherosclerotic Cardiovascular Disease
Phase 3
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
May 2027 (1)
RosuvastatinPhase 3Hypercholesterolaemia
Est. primary completion 2027-05-28 · NCT07619118 · CT.gov ↗
What to watch
July 2027 (1)
RosuvastatinPhase 3Hypercholesterolaemia
Est. primary completion 2027-07-30 · NCT07619131 · CT.gov ↗
What to watch
August 2027 (2)
TapinarofPhase 3Atopic Dermatitis
Est. primary completion 2027-08 · NCT07265479 · CT.gov ↗
What to watch
DalcetrapibPhase 3Acute Coronary Syndrome
Est. primary completion 2027-08 · NCT05918861 · CT.gov ↗
What to watch
October 2027 (1)
RosuvastatinPhase 3Hypercholesterolemia
Est. primary completion 2027-10-11 · NCT07930507 · CT.gov ↗
What to watch
2032 (1)
September 2032 (1)
Est. primary completion 2032-09-14 · NCT07393659 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$3.3B$810M$4.5B—report ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.9B$714M$2.5B—report ↗
2024-FY$3.0B———report ↗
2023-FY$3.1B$753M$2.3B—report ↗
2022-FY$3.0B$648M$2.1B—report ↗
2021-FY$3.0B$648M$2.1B—report ↗